Long QT Syndrome News and Research

RSS

Long QT syndrome (LQTS) is a disease that affects the normal heart rhythm and electrical activity. It may lead to sudden onset and dangerous arrhythmias (irregularities of heart rate and rhythm) which may be brought on by triggers like exercise or stress.

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

7 Jul 2014

Scientists discover 23 new genes linked to heart rhythm

The QT interval is part of the heart's electrical cycle as measured by ECG, and represents the electrical depolarization and repolarization of the ventricles. Lengthened intervals indicate dysfunction in the heart beat and are liable to lead to a five-fold increase in the risk of sudden death from heart failure.

2 Jul 2014

Genetic variant linked to sudden cardiac death leads to protein overproduction in heart cells

A genetic variant linked to sudden cardiac death leads to protein overproduction in heart cells, Johns Hopkins scientists report. Unlike many known disease-linked variants, this one lies not in a gene but in so-called noncoding DNA, a growing focus of disease research.

28 May 2014

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.

11 Mar 2014

Copenhagen scientists study link between congenital arrhythmia and hypoglycemia

In a new study, scientists from University of Copenhagen document a connection between congenital arrhythmia and the bodies' ability to handle sugar. The results can be of vital importance for patients with the disease and for the future treatment of diabetes. The new study has just been published in the scientific journal Diabetes.

19 Dec 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

CDC and NIH collaborate to create Sudden Death in Young Registry

A registry of deaths in young people from conditions such as heart disease and epilepsy is being created to help researchers define the scope of the problem and set future research priorities. The National Institutes of Health and the Centers for Disease Control and Prevention are collaborating to create the Sudden Death in the Young Registry.

24 Oct 2013

NHCS researchers discover potential cure for long QT syndrome 2

The National Heart Centre Singapore research team has successfully and completely reversed the effects of the hERG (human ether-a-go-go-related gene) mutation in long QT syndrome 2 in patient-specific heart cells, scoring a world's first.

18 Sep 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013

$Study shows VATS-LCSD can help children with refractory cardiac arrhythmias$

Study shows VATS-LCSD can help children with refractory cardiac arrhythmias

Inherited ventricular arrhythmias are an important cause of morbidity and sudden cardiac death in children who have structurally normal hearts. Despite conventional medical therapy, some of these children remain symptomatic with recurrent life-threatening arrhythmias, syncope, or frequent discharges from implantable cardioverter defibrillators.

8 May 2013

Mayo Clinic implements electronic warning system to identify patients at risk of QT-related deaths

Using a one-of-a-kind computer-aided program, Mayo Clinic has developed and implemented a Mayo-wide electronic warning system to identify patients at risk of QT-related deaths from an abnormality in the heart's electrical system.

26 Apr 2013

Researchers discover genetic variants of heart disorder in some cases of stillbirth

In a first-of-its-kind study, researchers from the United States and Europe discovered genetic mutations associated with long QT syndrome, a genetic abnormality in the heart's electrical system, in a small number of intrauterine fetal deaths, according to a study in the April 10 issue of the Journal of the American Medical Association.

10 Apr 2013

Investigators discover two new genes associated with severe early-onset disorders of heart rhythm

A team led by Vanderbilt University investigators has discovered two new genes - both coding for the signaling protein calmodulin - associated with severe early-onset disorders of heart rhythm.

7 Feb 2013

Researchers find new genetic differences in human hearts

Healthy men and women show little difference in their hearts, except for small electrocardiographic disparities. But new genetic differences found by Washington University in St. Louis researchers in hearts with disease could ultimately lead to personalized treatment of various heart ailments.

25 Jan 2013

$Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer$

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.

3 Jan 2013

Exercise clue to long QT syndrome prognosis

The size of reduction in heart rate immediately after exercise is associated with the presence of arrhythmias in patients with long QT syndrome type 1, report researchers.

18 Dec 2012

Computer simulation can predict risk of irregular heart rhythms and sudden cardiac death

A computer model of the heart wall predicted risk of irregular heart rhythms and sudden cardiac death in patients, paving the way for the use of more complex cardiac models to calculate the consequences of genetic, lifestyle and other changes to the heart.

14 Dec 2012